CA
NZ
UK
AU
IND
US
● Creative Medical Technology Holdings bought 4,000,000 BioDefense, Inc. shares from CreativeAcquisitionCorp effective September 24, 2026, paying $200,000 in cash plus 1,000,000 CELZ shares.
● Clover Health filed an 8-K/A on September 25, 2026 solely to correct an administrative error in the title of a press release exhibit, restating that former U.S. Senator Robert Torricelli and physician Dr. Brian J. Miller joined the board effective September 22, 2026.
● ADARx Pharmaceuticals priced an upsized IPO at $17 a share, raising $446.3 million, and shares soared in their first session on theNasdaqComposite.
● Addex Therapeutics announced in a 6-K filed September 25, 2026 that it regained full global rights to its GABAB positive allosteric modulator portfolio for substance use disorders from Indivior UK Limited.
On Friday, UnitedHealth (NYSE:UNH) nudged higher on the Dow Jones Industrial Average, carried along by a sharp rally in rival Humana (NYSE:HUM). There was no reported UnitedHealth-specific catalyst; the move was a classic case of sympathy trading within the managed-care group.
● Adagene Inc. furnished a Form 6-K disclosing that Executive Director of Finance Chunfang (Vicky) Gu will step down effective September 30, 2026, citing personal reasons.
Medtronic edged higher on Friday, carried by a firmer healthcare sector rather than any news of its own, on a day when the S&P 500 closed out a winning week.
Moderna climbed to a new 52-week high on Friday as momentum around its melanoma cancerVaccinedata kept drawing buyers, even on a day when biotech as a group was weak.
Moderna kept climbing on Friday, touching a new 52-week high, as Bernstein reiterated its rating with a $45 target and enthusiasm around its melanoma vaccine showed no sign of fading.
Humana soared on Friday after Barclays upgraded the health insurer to Overweight and lifted its price target from $407 to $515, pulling UnitedHealth modestly higher in sympathy.
Please wait processing your request...